Revenue

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

With women as just 4% of skilled trade workers, a Tulsa company is leading a charge to recruit them into high-paying, in-demand careers.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Ituran announces a $30M dividend after a record year, leveraging a unique Israeli tax law to boost shareholder returns and signaling deep confidence.

Investors eye Moody's CEO Rob Fauber's upcoming speech for insights on AI strategy, M&A forecasts, and navigating an increasingly complex global economy.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

Struggling manufacturer Highway Holdings acquires a 51% stake in Germany's Regent-Feinbau, a bold move to enter high-value markets and build resilient supply chains.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Top-ranked US advisory firm LSP enters Europe's heated market, tapping veteran Humza Vanderman to lead its new London hub amid a surge in activism.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.

As Singapore mandates e-invoicing, Cygnet.One leverages its global platform to simplify complex digital tax compliance for multinational enterprises.

The burger giant defied economic headwinds in 2025, posting record growth thanks to a key acquisition, new stores, and a focus on affordability.

Houston's largest credit union wins its second Gallup award in three years. We explore the strategy connecting happy employees to a thriving bottom line.

1 Hotel Tokyo debuts in Akasaka, fusing biophilic design with Japanese craft to set a new standard for planet-first luxury and holistic wellness.